The estimated Net Worth of Kerry Wentworth is at least $1.47 million dollars as of 19 July 2021. Ms. Wentworth owns over 3,944 units of Flexion Therapeutics Inc stock worth over $1,289,927 and over the last 18 years she sold FLXN stock worth over $176,164. In addition, she makes $0 as Chief Regulatory Officer at Flexion Therapeutics Inc.
Kerry has made over 8 trades of the Flexion Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently she sold 3,944 units of FLXN stock worth $25,439 on 19 July 2021.
The largest trade she's ever made was selling 13,988 units of Flexion Therapeutics Inc stock on 27 December 2011 worth over $28,675. On average, Kerry trades about 713 units every 57 days since 2006. As of 19 July 2021 she still owns at least 140,362 units of Flexion Therapeutics Inc stock.
You can see the complete history of Ms. Wentworth stock trades at the bottom of the page.
Kerry Wentworth serves as Chief Regulatory Officer of the Company. Ms. Wentworth was appointed as our Chief Regulatory Officer in December 2017 and was previously our Senior Vice President of Regulatory Affairs & Quality. Prior to joining us in 2014, Ms. Wentworth served as Vice President, Clinical, Regulatory and Quality at Agenus, Inc., where she was responsible for leading all global regulatory and clinical development efforts for nearly 10 years. Previously, Ms. Wentworth led the Regulatory and Quality function for Genelabs Technologies, Inc., where she was responsible for advancing their lead program through Phase 3 development and into the registration phase with FDA and EMA. Ms. Wentworth also held positions of increasing responsibility within Regulatory Affairs at Genzyme. Ms. Wentworth holds a BS in pre-veterinary medicine from the University of New Hampshire.
Kerry Wentworth is 47, she's been the Chief Regulatory Officer of Flexion Therapeutics Inc since 2017. There are 15 older and no younger executives at Flexion Therapeutics Inc. The oldest executive at Flexion Therapeutics Inc is Samuel Colella, 80, who is the Independent Director.
Kerry's mailing address filed with the SEC is C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON, MA, 01803.
Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon et Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.
Flexion Therapeutics Inc executives and other stock owners filed with the SEC include: